IN2012DN02778A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02778A IN2012DN02778A IN2778DEN2012A IN2012DN02778A IN 2012DN02778 A IN2012DN02778 A IN 2012DN02778A IN 2778DEN2012 A IN2778DEN2012 A IN 2778DEN2012A IN 2012DN02778 A IN2012DN02778 A IN 2012DN02778A
- Authority
- IN
- India
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
- A61K39/39525—Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25341109P | 2009-10-20 | 2009-10-20 | |
| PCT/US2010/053388 WO2011050071A2 (en) | 2009-10-20 | 2010-10-20 | Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN02778A true IN2012DN02778A (en) | 2015-09-18 |
Family
ID=43900936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2778DEN2012 IN2012DN02778A (en) | 2009-10-20 | 2012-03-30 |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US8491904B2 (en) |
| EP (2) | EP2491055A2 (en) |
| JP (1) | JP5914342B2 (en) |
| KR (2) | KR20170136649A (en) |
| CN (2) | CN104744560A (en) |
| AU (1) | AU2010310748C1 (en) |
| BR (1) | BR112012009289B8 (en) |
| CA (1) | CA2775595A1 (en) |
| CY (1) | CY1123952T1 (en) |
| DK (1) | DK3037104T3 (en) |
| ES (1) | ES2813398T3 (en) |
| HR (1) | HRP20201118T1 (en) |
| HU (1) | HUE053489T2 (en) |
| IL (1) | IL218897A (en) |
| IN (1) | IN2012DN02778A (en) |
| LT (1) | LT3037104T (en) |
| MX (2) | MX341136B (en) |
| NZ (2) | NZ627668A (en) |
| PL (1) | PL3037104T3 (en) |
| PT (1) | PT3037104T (en) |
| RS (1) | RS60577B1 (en) |
| RU (1) | RU2603055C2 (en) |
| SG (1) | SG10201406713XA (en) |
| SI (1) | SI3037104T1 (en) |
| SM (1) | SMT202000470T1 (en) |
| TW (1) | TWI515202B (en) |
| WO (1) | WO2011050071A2 (en) |
| ZA (1) | ZA201202720B (en) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2468232B (en) * | 2007-11-30 | 2012-10-24 | Glaxo Group Ltd | Antigen-bindng constructs |
| SG195577A1 (en) | 2008-10-20 | 2013-12-30 | Abbott Lab | Viral inactivation during purification of antibodies |
| CN102257006A (en) * | 2008-10-20 | 2011-11-23 | 雅培制药有限公司 | Isolation and purification of antibodies using protein a affinity chromatography |
| US8491904B2 (en) | 2009-10-20 | 2013-07-23 | Abbvie Inc. | Isolation and purification of anti-IL-13 antibodies using protein A affinity chromatography |
| JP2013535683A (en) | 2010-07-30 | 2013-09-12 | イー・エム・デイー・ミリポア・コーポレイシヨン | Chromatographic media and method |
| AR085911A1 (en) | 2011-03-16 | 2013-11-06 | Sanofi Sa | SAFE THERAPEUTIC DOSE OF A SIMILAR PROTEIN TO AN ANTIBODY WITH VUAL REGION |
| JP2015513674A (en) * | 2012-02-27 | 2015-05-14 | バイオジェン アイデック エムエー インコーポレイティドＢｉｏｇｅｎ Ｉｄｅｃ Ｉｎｃ． | High-throughput method for sialic acid determination |
| JP6592426B2 (en) | 2013-03-15 | 2019-10-16 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | Protein purification using hydrophobic interaction chromatography under salt-free conditions |
| US10259842B2 (en) * | 2013-05-15 | 2019-04-16 | Medimmune, Llc | Purification of recombinantly produced polypeptides |
| TWI596107B (en) | 2013-06-25 | 2017-08-21 | 卡地拉保健有限公司 | Novel purification process for monoclonal antibodies |
| JP6141524B2 (en) | 2013-07-12 | 2017-06-07 | メルク パテント ゲーエムベーハー | Fragment removal from target protein-containing samples using activated carbon |
| AU2014318615B2 (en) * | 2013-09-13 | 2020-03-12 | Genentech, Inc. | Methods and compositions comprising purified recombinant polypeptides |
| JP6546178B2 (en) | 2013-09-13 | 2019-07-17 | ジェネンテック， インコーポレイテッド | Compositions and methods for detecting and quantifying host cell proteins and recombinant polypeptide products in cell lines |
| EP3048109A4 (en) * | 2013-09-17 | 2017-04-19 | Kaneka Corporation | Novel antibody purification method and antibody obtained therefrom, and novel antibody purification method using cation exchanger and antibody obtained therefrom |
| CN105017418B (en) * | 2014-03-27 | 2021-02-23 | 上海药明康德新药开发有限公司 | Monoclonal antibody purification process |
| FR3025515B1 (en) * | 2014-09-05 | 2016-09-09 | Lab Francais Du Fractionnement | PROCESS FOR PURIFYING MONOCLONAL ANTIBODY |
| TW201628649A (en) | 2014-10-09 | 2016-08-16 | 再生元醫藥公司 | Method for reducing microscopic particles in a pharmaceutical formulation |
| EP3230299A1 (en) | 2014-12-08 | 2017-10-18 | EMD Millipore Corporation | Mixed bed ion exchange adsorber |
| FI3334747T3 (en) | 2015-08-13 | 2023-11-30 | Amgen Inc | CHARGED DEEP FILTRATION OF ANTIGEN-BINDING PROTEINS |
| BR112018003127A2 (en) * | 2015-08-20 | 2018-09-25 | Genentech Inc | fkpa purification and uses thereof to produce recombinant polypeptides |
| FI3448391T3 (en) * | 2016-04-27 | 2024-06-19 | Abbvie Mfg Management Unlimited Company | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies |
| BR112019000872A2 (en) | 2016-08-16 | 2019-04-30 | Regeneron Pharmaceuticals, Inc. | methods for quantifying individual antibodies in a mixture |
| AU2017350807B2 (en) | 2016-10-25 | 2022-07-07 | Regeneron Pharmaceuticals, Inc. | Methods and systems for chromatography data analysis |
| EP4252629A3 (en) | 2016-12-07 | 2023-12-27 | Biora Therapeutics, Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3233933A1 (en) * | 2017-01-30 | 2018-08-02 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for reducing bioburden in chromatography |
| WO2018183932A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor |
| AR111465A1 (en) * | 2017-04-14 | 2019-07-17 | Cj Healthcare Corp | METHOD FOR PURIFICATION OF ANALOG ANTIBODIES BY THE USE OF CATION EXCHANGE CHROMATOGRAPHY |
| WO2019036626A1 (en) * | 2017-08-17 | 2019-02-21 | Just Biotherapeutics, Inc. | Method of purifying glycosylated protein from host cell galectins and other contaminants |
| IL272954B2 (en) | 2017-09-19 | 2024-06-01 | Regeneron Pharma | Methods of reducing particle formation and compositions formed thereby |
| TW202448568A (en) | 2018-07-02 | 2024-12-16 | 美商里珍納龍藥品有限公司 | Systems and methods for preparing a polypeptide from a mixture |
| JPWO2020022363A1 (en) * | 2018-07-25 | 2021-08-02 | 第一三共株式会社 | Effective method for producing antibody-drug conjugates |
| AU2019311596A1 (en) | 2018-07-27 | 2021-01-28 | Daiichi Sankyo Company, Limited | Protein recognizing drug moiety of antibody-drug conjugate |
| CN110818789B (en) * | 2018-08-07 | 2023-02-28 | 三生国健药业（上海）股份有限公司 | Purification method of high-purity cynomolgus monkey interleukin 17A |
| CN116726361A (en) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | Methods and devices for treating disease with biotherapeutics |
| TWI871300B (en) * | 2019-01-28 | 2025-02-01 | 美商安進公司 | A continuous manufacturing process for biologics manufacturing by integration of drug substance and drug product processes |
| AR119097A1 (en) * | 2019-06-05 | 2021-11-24 | Seattle Genetics Inc | PURIFICATION METHODS OF MASKED ANTIBODIES |
| EP4007766A1 (en) * | 2019-08-01 | 2022-06-08 | Regeneron Pharmaceuticals, Inc. | Method for viral inactivation |
| WO2021112926A1 (en) | 2019-12-06 | 2021-06-10 | Regeneron Pharmaceuticals, Inc. | Anti-vegf protein compositions and methods for producing the same |
| WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| IL294677A (en) * | 2020-01-17 | 2022-09-01 | Regeneron Pharma | Hydrophobic interaction chromatography for viral purification |
| US12103960B2 (en) | 2020-05-08 | 2024-10-01 | Regeneron Pharmaceuticals, Inc. | VEGF traps and mini-traps and methods for treating ocular disorders and cancer |
| CN112326966A (en) * | 2020-11-02 | 2021-02-05 | 杭州昱鼎生物科技有限公司 | Novel rapid detection kit for coronavirus antigen, and preparation method and application thereof |
| WO2025029614A1 (en) * | 2023-07-28 | 2025-02-06 | Amgen Inc. | A method for equilibrating a chromatography medium |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE266710C (en) | ||||
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4534972A (en) | 1983-03-29 | 1985-08-13 | Miles Laboratories, Inc. | Protein compositions substantially free from infectious agents |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (en) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Process for the biotechnical production of alkaline phosphatase |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| ATE135370T1 (en) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ATE185601T1 (en) | 1990-07-10 | 1999-10-15 | Cambridge Antibody Tech | METHOD FOR PRODUCING SPECIFIC BONDING PAIRS |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| DE4041205A1 (en) | 1990-12-21 | 1992-06-25 | Schloemann Siemag Ag | Hot rolling of strip from thin cast sections |
| AU1545692A (en) | 1991-03-01 | 1992-10-06 | Protein Engineering Corporation | Process for the development of binding mini-proteins |
| DE69233750D1 (en) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Libraries of heterodimeric receptors using phagemids |
| DE4122599C2 (en) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid for screening antibodies |
| US5457178A (en) * | 1993-07-07 | 1995-10-10 | Fmc Corporation | Insecticidally effective spider toxin |
| US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| EP0871436A4 (en) * | 1995-06-30 | 1999-10-20 | Smithkline Beecham Corp | USE OF Stat 6 SH2 DOMAIN SPECIFIC COMPOUNDS TO TREAT ALLERGIC REACTIONS |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| US6955917B2 (en) * | 1997-06-20 | 2005-10-18 | Bayer Healthcare Llc | Chromatographic method for high yield purification and viral inactivation of antibodies |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| CN100448992C (en) | 2001-05-11 | 2009-01-07 | 麒麟医药株式会社 | Human Artificial Chromosome Containing Human Antibody λ Light Chain Gene |
| US7646782B1 (en) | 2001-07-30 | 2010-01-12 | Primrose Donald R | Data link/physical layer packet buffering and flushing |
| JP2006508062A (en) * | 2002-09-17 | 2006-03-09 | ジーティーシー バイオセラピューティックス インコーポレイテッド | Isolation of immunoglobulin molecules lacking inter-heavy chain disulfide bonds. |
| AU2004215653B2 (en) * | 2003-02-28 | 2011-03-17 | Lonza Biologics Plc. | Antibody purification by protein A and ion exchange chromatography |
| GB0304576D0 (en) * | 2003-02-28 | 2003-04-02 | Lonza Biologics Plc | Protein a chromatography |
| DK1678208T3 (en) * | 2003-10-27 | 2013-07-08 | Wyeth Llc | REMOVAL OF HIGH MOLECULAR WEIGHT AGGREGATES USING HYDROXYAPATITE CHROMATOGRAPHY |
| DE102004027816A1 (en) * | 2004-06-08 | 2006-01-05 | Bioceuticals Arzneimittel Ag | Process for the purification of erythropoietin |
| AR049390A1 (en) | 2004-06-09 | 2006-07-26 | Wyeth Corp | ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME |
| TWI307630B (en) * | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| US20080248048A1 (en) | 2005-09-30 | 2008-10-09 | Astrazeneca Ab | Interleukin-13 Antibody Composition |
| GB0600488D0 (en) | 2006-01-11 | 2006-02-22 | Glaxo Group Ltd | Immunoglobulins |
| EP2738178A1 (en) | 2006-04-05 | 2014-06-04 | AbbVie Biotechnology Ltd | Antibody purification |
| KR101385927B1 (en) * | 2006-04-20 | 2014-04-24 | 와이어쓰 엘엘씨 | Purification processes for isolating purified vesicular stomatitis virus from cell culture |
| WO2009017491A1 (en) * | 2006-06-14 | 2009-02-05 | Smithkline Beecham Corporation | Methods for purifying antibodies using ceramic hydroxyapatite |
| SG10201508485UA (en) * | 2006-09-08 | 2015-11-27 | Abbvie Bahamas Ltd | Interleukin - 13 binding proteins |
| SG195577A1 (en) * | 2008-10-20 | 2013-12-30 | Abbott Lab | Viral inactivation during purification of antibodies |
| WO2010147686A2 (en) * | 2009-03-11 | 2010-12-23 | Wyeth Llc | Methods of purifying small modular immunopharmaceutical proteins |
| US8491904B2 (en) | 2009-10-20 | 2013-07-23 | Abbvie Inc. | Isolation and purification of anti-IL-13 antibodies using protein A affinity chromatography |
-
2010
- 2010-10-20 US US12/908,502 patent/US8491904B2/en active Active
- 2010-10-20 SI SI201032028T patent/SI3037104T1/en unknown
- 2010-10-20 CA CA2775595A patent/CA2775595A1/en not_active Abandoned
- 2010-10-20 RS RS20200864A patent/RS60577B1/en unknown
- 2010-10-20 WO PCT/US2010/053388 patent/WO2011050071A2/en not_active Application Discontinuation
- 2010-10-20 RU RU2012120751/10A patent/RU2603055C2/en active
- 2010-10-20 PL PL15189425T patent/PL3037104T3/en unknown
- 2010-10-20 EP EP10777144A patent/EP2491055A2/en not_active Withdrawn
- 2010-10-20 AU AU2010310748A patent/AU2010310748C1/en not_active Ceased
- 2010-10-20 KR KR1020177034448A patent/KR20170136649A/en not_active Ceased
- 2010-10-20 ES ES15189425T patent/ES2813398T3/en active Active
- 2010-10-20 PT PT151894250T patent/PT3037104T/en unknown
- 2010-10-20 JP JP2012535337A patent/JP5914342B2/en active Active
- 2010-10-20 CN CN201510208066.4A patent/CN104744560A/en active Pending
- 2010-10-20 KR KR1020127012851A patent/KR101830596B1/en active Active
- 2010-10-20 CN CN201080057917.5A patent/CN102711828B/en active Active
- 2010-10-20 MX MX2014006213A patent/MX341136B/en unknown
- 2010-10-20 BR BR112012009289A patent/BR112012009289B8/en active IP Right Grant
- 2010-10-20 LT LTEP15189425.0T patent/LT3037104T/en unknown
- 2010-10-20 EP EP15189425.0A patent/EP3037104B1/en active Active
- 2010-10-20 SG SG10201406713XA patent/SG10201406713XA/en unknown
- 2010-10-20 NZ NZ627668A patent/NZ627668A/en not_active IP Right Cessation
- 2010-10-20 MX MX2012004711A patent/MX2012004711A/en active IP Right Grant
- 2010-10-20 TW TW099135795A patent/TWI515202B/en active
- 2010-10-20 NZ NZ599100A patent/NZ599100A/en not_active IP Right Cessation
- 2010-10-20 DK DK15189425.0T patent/DK3037104T3/en active
- 2010-10-20 HU HUE15189425A patent/HUE053489T2/en unknown
- 2010-10-20 SM SM20200470T patent/SMT202000470T1/en unknown
-
2012
- 2012-03-27 IL IL218897A patent/IL218897A/en active IP Right Grant
- 2012-03-30 IN IN2778DEN2012 patent/IN2012DN02778A/en unknown
- 2012-04-13 ZA ZA2012/02720A patent/ZA201202720B/en unknown
-
2013
- 2013-07-09 US US13/937,946 patent/US9266950B2/en active Active
-
2016
- 2016-01-19 US US15/000,831 patent/US9975948B2/en active Active
-
2018
- 2018-04-06 US US15/947,085 patent/US11390668B2/en active Active
-
2020
- 2020-07-15 HR HRP20201118TT patent/HRP20201118T1/en unknown
- 2020-08-21 CY CY20201100781T patent/CY1123952T1/en unknown
-
2022
- 2022-05-17 US US17/745,982 patent/US12157767B2/en active Active